PMID- 35117268
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230917
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct
TI  - Current perspectives on novel systemic therapeutic agents beyond immune 
      checkpoint inhibition in metastatic urothelial carcinoma.
PG  - 6583-6588
LID - 10.21037/tcr-20-1262 [doi]
AB  - Treatment strategies for metastatic urothelial carcinoma (mUC) have evolved 
      dramatically over the last decade. The emergence of immunotherapeutic agents, 
      especially immune checkpoint inhibitors, has been the most significant 
      development. Immunotherapy increased the overall survival rate of patients with 
      mUC and provided a durable response. The success of immune checkpoint inhibitors 
      further led to the development of novel agents that regulate the immune system 
      within the tumor microenvironment. However, despite some success with immune 
      checkpoint inhibitors, researchers are still developing new agents, including 
      small molecule tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) 
      inhibitors, and novel fusion proteins, tailored for targets other than immune 
      checkpoint inhibitors. Novel treatment strategies are being developed rapidly 
      with ongoing pre-clinical trials. Here, we outline promising new therapies that 
      are expected to improve survival rates for patients with mUC.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Choi, Hoon
AU  - Choi H
AD  - Department of Urology, Korea University Medical Center, Korea University School 
      of Medicine, Ansan 15355, Korea.
FAU - Park, Jae Young
AU  - Park JY
AD  - Department of Urology, Korea University Medical Center, Korea University School 
      of Medicine, Ansan 15355, Korea.
FAU - Bae, Jae Hyun
AU  - Bae JH
AD  - Department of Urology, Korea University Medical Center, Korea University School 
      of Medicine, Ansan 15355, Korea.
FAU - Tae, Bum Sik
AU  - Tae BS
AD  - Department of Urology, Korea University Medical Center, Korea University School 
      of Medicine, Ansan 15355, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8799034
OTO - NOTNLM
OT  - Metastatic urothelial carcinoma (mUC)
OT  - chemotherapy
OT  - novel
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-1262). The series 
      "Urothelial Carcinoma" was commissioned by the editorial office without any 
      funding or sponsorship. The authors have no other conflicts of interest to 
      declare.
EDAT- 2020/10/01 00:00
MHDA- 2020/10/01 00:01
PMCR- 2020/10/01
CRDT- 2022/02/04 05:50
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2022/02/04 05:50 [entrez]
PHST- 2020/10/01 00:00 [pubmed]
PHST- 2020/10/01 00:01 [medline]
PHST- 2020/10/01 00:00 [pmc-release]
AID - tcr-09-10-6583 [pii]
AID - 10.21037/tcr-20-1262 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Oct;9(10):6583-6588. doi: 10.21037/tcr-20-1262.